חזרה לתוצאות החיפוש

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

ישראלמגייס משתתפיםPHASE2

מצבים רפואיים

Aortic Stenosis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Heart Center Research Llc, Huntsville, Alabama, United States

    Contact: Study coordinator (Amy Williams) · awilliams@theheartcenter.md · +1 256 519 8255
    Contact: Principal Investigator (Vernon R Hunter)

  • Cardiovascular Res Found, Beverly Hills, California, United States

    Contact: Study coordinator (Juan Ramos) · juan.ramos@cvmg.com · +1 310 278 3400
    Contact: Principal Investigator (Ronald P Karlsberg)

  • National Heart Institute, Beverly Hills, California, United States

    Contact: Study coordinator (Maria Flores) · mflores@nationalheartinstitute.org · +1 301 289 5221
    Contact: Principal Investigator (Norman Lepor)

  • Flourish Clinical Resrch Covin, Covina, California, United States

    Contact: Study coordinator (Sarita Garcia) · sgarcia@flourishresearch.com · +1 714 299 2412
    Contact: Principal Investigator (Fahed Bitar)

  • Valley Clinical Trials, Northridge, California, United States

    Contact: Study coordinator (Haydee Gutierrez) · haydee@valleyclinicaltrials.com · +1 818 280 4220
    Contact: Principal Investigator (Mehrdad Ariani)

  • Stanford University Medical Center, Palo Alto, California, United States

    Contact: Study coordinator (Tamara Bazouzi) · bazouzit@stanford.edu · +1 650 736 7878
    Contact: Principal Investigator (Abha Khandelwal)

  • University Of California San Diego, San Diego, California, United States

    Contact: Study coordinator (Ruby Swaim) · rswaim@health.ucsd.edu · +1 858 246 2510
    Contact: Principal Investigator (Anna Narezkina)

  • UC San Francisco Medical Center, San Francisco, California, United States

    Contact: Study coordinator (Liliann Zou) · liliann.zou@ucsf.edu · +1 415 514 3156
    Contact: Principal Investigator (Eveline Stock)

  • Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States

  • Nova Clinical Research LLC, Bradenton, Florida, United States

    Contact: Study coordinator (Sade Andrews) · sade.andrews@novaclinicalresearch.com · +1 941 792 6564
    Contact: Principal Investigator (Christian Zellner)

  • Flourish Res Acq LLC North Miami, Miami, Florida, United States

    Contact: Study coordinator (Ashlee Sealy) · asealy@flourishresearch.com
    Contact: Principal Investigator (Rimsky Denis.)

  • Inpatient Research Clinical LLC, Miami Lakes, Florida, United States

    Contact: Study coordinator (Dora Gutierrez) · dgutierrez@inpatientresearch.com · +1 786 502 4303
    Contact: Principal Investigator (Alexis Gutierrez.)

  • Advanced Research for Health Improvement LLC, Naples, Florida, United States

  • Midwest Heart and Vascular Spec, Overland Park, Kansas, United States

    Contact: Study coordinator (Elizabeth Fulks) · Elizabeth.fulks@hcahealthcare.com · +1 913 253 3000
    Contact: Principal Investigator (Vasvi Singh.)

  • Tufts Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Juan Carlos Collado Falcon) · juan.carlos.collado.falcon@tuftsmedicine.org · +1 617 636 5897
    Contact: Principal Investigator (Benjamin Wessler)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Victoria Viscosi) · vviscosi@mgh.harvard.edu · +1 813 943 3440
    Contact: Principal Investigator (Michael Honigberg)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Victoria Viscosi) · vviscosi@mgh.harvard.edu
    Contact: Principal Investigator (Michael Honigberg)

  • Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States

    Contact: Study coordinator (Sam Wong) · swong1@bwh.harvard.edu · +1 617 347 8680
    Contact: Principal Investigator (Rhanderson Cardoso)

  • Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States

    Contact: Study coordinator (Sam Wong) · swong1@bwh.harvard.edu · +1 617 525 1227
    Contact: Principal Investigator (Rhanderson Cardoso)

  • Henry Ford Hospital, Detroit, Michigan, United States

    Contact: Study coordinator (Jodi Carter, BS, CCRP) · +1 (313) 916-3613
    Contact: Principal Investigator (Khaled Abdul-Nour)

  • Henry Ford Hospital, Detroit, Michigan, United States

    Contact: Study coordinator (Jodi Carter) · jcarte23@hfhs.org · +1 313 590 2407
    Contact: Principal Investigator (Khaled Abdul-Nour)

  • AA Medical Research Center, Flint, Michigan, United States

    Contact: Study coordinator (Fayyaz Shah) · fshah@aamrc.net · +1 810 237 1125
    Contact: Principal Investigator (Ahmed A Arif.)

  • William Beaumont Hospital, Royal Oak, Michigan, United States

    Contact: Study coordinator (Rachel Wylie) · rachel.wylie@corewellhealth.org · +1 248 551 4192
    Contact: Principal Investigator (Joel Skaistis)

  • Minneapolis Heart Institute, Minneapolis, Minnesota, United States

  • University Of Minnesota, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Michelle Pitt) · henni032@umn.edu · +1 612 624 4948
    Contact: Principal Investigator (Daniel Duprez)

  • Overlook Medical Center, Summit, New Jersey, United States

    Contact: Study coordinator (Rosmery Montesino) · Rosmery.montesino@atlantichealth.org · +1 908 522 6279
    Contact: Principal Investigator (Robert Fishberg.)

  • Capital Cardiology Associates, Albany, New York, United States

    Contact: Study coordinator (Shreya Shah) · sshah@capitalcardiology.com
    Contact: Principal Investigator (Lance Sullenberger.)

  • New York Presbyterian Hospital, New York, New York, United States

  • Icahn School of Med at Mt Sinai, New York, New York, United States

    Contact: Study coordinator (Jay Krishna Katragadda) · jaykrishna.katragadda@mssm.edu · +1 212 659 9174
    Contact: Principal Investigator (Robert Rosenson.)

  • Strong Memorial Hospital, Rochester, New York, United States

    Contact: Study coordinator (Ferogh Shakouri) · ferogh_shakouri@URMC.Rochester.edu · +1 716 275 7753
    Contact: Principal Investigator (Robert Block)

  • Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Donna Davis) · donna.h.davis@advocatehealth.org
    Contact: Principal Investigator (Michael Shapiro)

  • Lindner Ctr At The Christ Hosp, Cincinnati, Ohio, United States

    Contact: Study coordinator (Meghan Grone) · Meghan.Grone@thechristhospital.com · +1 513 585 1777
    Contact: Principal Investigator (Sitaramesh Emani)

  • Ohio State University, Columbus, Ohio, United States

  • Perelman School of Medicine, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Manali Shah) · manali.shah2@pennmedicine.upenn.edu
    Contact: Principal Investigator (Archna Bajaj)

  • Orion Medical, Houston, Texas, United States

    Contact: Study coordinator (Lena Olivera Perez) · lena.oliveraperez@usheartandvascular.com
    Contact: Principal Investigator (Karan Bhalla)

  • Virginia Heart, Falls Church, Virginia, United States

    Contact: Study coordinator (Samira Kamali) · skamali@VirginiaHeart.com · +1 703 766 5920
    Contact: Principal Investigator (Tariq Haddad)

  • Carient Heart and Vascular, Manassas, Virginia, United States

    Contact: Study coordinator (Hameeda Tasneem) · htasneem@carient.com · +1 70 333 58 750
    Contact: Principal Investigator (Vikram Prasanna)

  • Novartis Investigative Site, Innsbruck, Tyrol, Austria

  • Novartis Investigative Site, Linz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Genk, Limburg, Belgium

  • Novartis Investigative Site, Yvoir, Namur, Belgium

  • Novartis Investigative Site, Aalst, Oost Vlaanderen, Belgium

  • Novartis Investigative Site, Kortrijk, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Cambridge, Ontario, Canada

  • Novartis Investigative Site, North York, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Hradec Králové, Czechia

  • Novartis Investigative Site, Jaroměř, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Esbjerg, Denmark

  • Novartis Investigative Site, Hvidovre, Denmark

  • Novartis Investigative Site, Roskilde, Denmark

  • Novartis Investigative Site, Viborg, Denmark

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Pessac, France

  • Novartis Investigative Site, Poitiers, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Kaiserslautern, Rhineland-Palatinate, Germany

  • Novartis Investigative Site, Dresden, Saxony, Germany

  • Novartis Investigative Site, Leipzig, Saxony, Germany

  • Novartis Investigative Site, Ahaus, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Bonn, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Lüneburg, Germany

  • Novartis Investigative Site, Mannheim, Germany

  • Novartis Investigative Site, München, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Oldenburg, Germany

  • Novartis Investigative Site, Beersheba, Israel

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Nahariya, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Ancona, AN, Italy

  • Novartis Investigative Site, Bergamo, BG, Italy

  • Novartis Investigative Site, Bologna, BO, Italy

  • Novartis Investigative Site, Brescia, BS, Italy

  • Novartis Investigative Site, Caserta, CE, Italy

  • Novartis Investigative Site, Cona, FE, Italy

  • Novartis Investigative Site, Pozzilli, IS, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Padova, PD, Italy

  • Novartis Investigative Site, Pordenone, PN, Italy

  • Novartis Investigative Site, Amsterdam, North Holland, Netherlands

  • Novartis Investigative Site, Amsterdam, North Holland, Netherlands

  • Novartis Investigative Site, Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site, Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site, Nieuwegein, Utrecht, Netherlands

  • Novartis Investigative Site, Alcabideche, Portugal

  • Novartis Investigative Site, Braga, Portugal

  • Novartis Investigative Site, Coimbra, Portugal

  • Novartis Investigative Site, Vila Nova de Gaia, Portugal

  • Novartis Investigative Site, Cáceres, Extremadura, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Basel, Switzerland

  • Novartis Investigative Site, Geneva, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

  • Novartis Investigative Site, Lugano, Switzerland

  • Novartis Investigative Site, Zurich, Switzerland

  • Novartis Investigative Site, Reading, Berkshire, United Kingdom

  • Novartis Investigative Site, Portadown, Nothern Ireland, United Kingdom

  • Novartis Investigative Site, Edinburgh, United Kingdom

  • Novartis Investigative Site, Leicester, United Kingdom

  • Novartis Investigative Site, Liverpool, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Londonderry, United Kingdom

  • Novartis Investigative Site, Manchester, United Kingdom

  • Novartis Investigative Site, Middlesbrough, United Kingdom

  • Novartis Investigative Site, Norwich, United Kingdom

  • Novartis Investigative Site, Tyne and Wear, United Kingdom

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)פנייה לחוקר (אימייל)